Rexahn Pharmaceuticals Issues Additional Comments And Clarifications On Its Phase IIa Study Results Of Serdaxin In Major Depressive Disorder (MDD)
Links shared publicly online about this topic.
- 1,237total visits
Rexahn Pharmaceuticals Issues Additional Comments And Clarifications On Its Phase IIa Study Results Of Serdaxin In Major Depressive Disorder (MDD)
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered addi
View full resource at medicalnewstoday.com
Tags: Nervous System, Depression, Major Depression, Disease and Condition, Pharma, Oncology
Most Recently Shared on April 16, 2010 at 9:23 am By:
Rexahn Pharmaceuticals Issues Additional Comments And Clarifications On Its Phase IIa Study Results Of Serdaxin In Maj... http://mnt.to/3BjG
Also Shared By:
Advertisement
Peter H Brown
@PeterBrownPsy
Rexahn Pharmaceuticals Issues Additional Comments And Clarifications On Its Phase IIa Study Results Of Se.. http://mnt.to/f/3BjG #depression
1 year ago...